LifeMD is trading 6.72% up at $3.25, with no clear company-specific announcement, filing, earnings update, or analyst action dated September 14, 2026 identified in available coverage.
- B. Riley’s September 11 Buy-rating reaffirmation and near-$8 target provide positive background but do not directly establish the cause.
- Broader markets are declining, so macro sentiment does not explain the gain.